Regorafenib in the real-life clinical practice: data from the czech registry

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter T. Buchler
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors T. Buchler1, Z. Bortlicek2, K. Hejduk2, B. Melichar3, P. Pokorna4, Z. Linke4, L. Petruželka5, J. Finek6, J. Prausova7, K. Kubáčková8
  • 1Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic, /
  • 2Institute of Biostatistics and Analysis, Masaryk University, Brno, Czech Republic, /
  • 3Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic, /
  • 4University Hospital Motol, Praha, Czech Republic, /
  • 5Oncology 1st Medical Faculty of Charles University, Prague, Czech Republic, /
  • 6Department of Oncology and Radiotherapy, Plzen, Czech Republic, /
  • 7University Hospital Motol, Prague, Czech Republic, /
  • 8University Hospital in Motol, Prague, Czech Republic, /


Regorafenib, a potent multikinase inhibitor, is currently approved for the treatment in pretreated patients with metastatic colorectal cancer The CORECT registry is a non-interventional post-marketing database, gathering information about patients with colorectal cancer and treated with targeted agents